Hsbc Holdings PLC Mirati Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$41.99 - $62.38 $32.9 Million - $48.8 Million	783,092 New	783,092 $46 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $968,565 - $2.31 Million	23,469 New	23,469 $1.06 Million
Q2 2022 Aug 11, 2022	BUY	$39.16 - $88.71 $654,794 - $1.48 Million	16,721 Added 229.78%	23,998 $1.61 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $551,742 - $1.1 Million	7,277 New	7,277 $609,000
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $505,793 - $679,278	-3,828 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $551,232 - $688,006	3,828 New	3,828 $618,000
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $1.38 Million - $1.92 Million	-8,658 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $1.4 Million - $2.08 Million	8,658 New	8,658 $1.9 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $478,976 - $707,384	-4,229 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $304,530 - $509,129	4,229 New	4,229 $483,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.